Q1 Earnings Forecast for Ovid Therapeutics Issued By Wedbush

Ovid Therapeutics Inc. (NASDAQ:OVID) – Investment analysts at Wedbush raised their Q1 2025 EPS estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.13) per share for the quarter, up from their prior forecast of ($0.15). Wedbush currently has a “Outperform” rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at $0.88 EPS.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.19 million.

OVID has been the topic of several other reports. Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a research report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a research report on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $3.20.

Ovid Therapeutics Stock Performance

NASDAQ:OVID opened at $0.46 on Monday. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18. Ovid Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $3.45. The stock has a market cap of $32.72 million, a PE ratio of -0.98 and a beta of 0.29. The firm’s fifty day simple moving average is $0.63 and its 200-day simple moving average is $0.94.

Institutional Investors Weigh In On Ovid Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd lifted its holdings in Ovid Therapeutics by 46.2% in the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after purchasing an additional 12,076 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Ovid Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock valued at $1,555,000 after purchasing an additional 14,816 shares in the last quarter. Rhumbline Advisers lifted its holdings in Ovid Therapeutics by 22.3% in the 4th quarter. Rhumbline Advisers now owns 84,078 shares of the company’s stock valued at $79,000 after purchasing an additional 15,355 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Ovid Therapeutics by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its holdings in Ovid Therapeutics by 1.1% in the 4th quarter. Kennedy Capital Management LLC now owns 1,545,387 shares of the company’s stock valued at $1,443,000 after purchasing an additional 17,402 shares in the last quarter. 72.24% of the stock is currently owned by hedge funds and other institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.